Seasonal influenza immunisation in Europe. Overview of recommendations and vaccination coverage for three seasons: pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11)

Mereckiene, Jolita; Cotter, Suzanne; Nicoll, A; Lopalco, Pietro Luigi; Noori, Teymur; Weber, J. Todd; D’Ancona, Fortunato; Lévy-Brühl, Daniel; Dematte, L; Giambi, Cristina; Valentiner‐Branth, Palle; Stankiewicz, Iwona Paradowska; Appelgren, Eva; O’Flanagan, D; group, Collective the VENICE project gatekeepers

doi:10.2807/1560-7917.es2014.19.16.20780

Cited by 157 publications

(137 citation statements)

References 26 publications

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…Countries such as the Netherlands, which has attained the highest coverage in Europe in past seasons, might be able to offer strategies to increase uptake in Canada. 21 Other trends noted in Canada were also observed in the US, such as relatively stable coverage across time and the greatest proportion of vaccinations being provided in October and November. 17 Large variability in coverage between states has been reported in the US and in Australia.…”

Section: Discussionmentioning

confidence: 82%

Trends in influenza vaccine coverage and vaccine hesitancy in Canada, 2006/07 to 2013/14: results from cross-sectional survey data

Buchan

Kwong

2016

CMAJ Open

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 82%

Trends in influenza vaccine coverage and vaccine hesitancy in Canada, 2006/07 to 2013/14: results from cross-sectional survey data

Buchan

Kwong

2016

CMAJ Open

View full text Add to dashboard Cite

“…1 Measuring and reporting influenza vaccine effectiveness (IVE) against hospitalised outcome within the targeted population is critical to evaluate and adapt these strategies.…”

Section: Introductionmentioning

confidence: 99%

Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013–14: Results from the InNHOVE network

Rondy¹,

Castilla²,

Launay³

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

We conducted a multicentre test negative case control study to estimate the 2013-14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all 18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1) pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1) pdm09. It was respectively 61.4% (95%CI: ¡1.9;85.4), 39.4% (95%CI: ¡32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18-64, 65-79 and 80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: ¡145.3;65.4), 25.6% (95%CI: ¡36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18-64, 65-79 and 80 years. These results suggest a moderate and age varying effectiveness of the 2013-14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups.

show abstract

“…5 In European countries, vaccination is generally restricted to older adults and adults with chronic conditions, and their close contacts to reduce transmission. 6 In North America, annual influenza vaccination is universally recommended for all people aged 6 months and older. 7,8 There is uncertainty about the degree of influenza vaccine protection in groups at increased risk and older adults despite being target populations within many national immunization schedules.…”

mentioning

confidence: 99%

Effectiveness of the influenza vaccine in preventing admission to hospital and death in people with type 2 diabetes

Vámos

Pape

Ćurčin

et al. 2016

CMAJ

View full text Add to dashboard Cite

Background:The health burden caused by seasonal influenza is substantial. We sought to examine the effectiveness of influenza vaccination against admission to hospital for acute cardiovascular and respiratory conditions and all-cause death in people with type 2 diabetes. Methods:We conducted a retrospective cohort study using primary and secondary care data from the Clinical Practice Research Datalink in England, over a 7-year period between 2003/04 and 2009/10. We enrolled 124 503 adults with type 2 diabetes. Outcome measures included admission to hospital for acute myocardial infarction (MI), stroke, heart failure or pneumonia/influenza, and death. We fitted Poisson regression models for influenza and off-season periods to estimate incidence rate ratios (IRR) for cohorts who had and had not received the vaccine. We used estimates for the summer, when influenza activity is low, to adjust for residual confounding.Results: Study participants contributed to 623 591 person-years of observation during the 7-year study period. Vaccine recipients were older and had more comorbid conditions compared with nonrecipients. After we adjusted for covariates and residual confounding, vaccination was associated with significantly lower admission rates for stroke (IRR 0.70 Interpretation: In this cohort of patients with type 2 diabetes, influenza vaccination was associated with reductions in rates of admission to hospital for specific cardiovascular events. Efforts should be focused on improvements in vaccine uptake in this important target group as part of comprehensive secondary prevention. AbstractResearch CMAJ, October 4, 2016, 188 (14) E343

show abstract

Seasonal influenza immunisation in Europe. Overview of recommendations and vaccination coverage for three seasons: pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11)

Cited by 157 publications

References 26 publications

Trends in influenza vaccine coverage and vaccine hesitancy in Canada, 2006/07 to 2013/14: results from cross-sectional survey data

Trends in influenza vaccine coverage and vaccine hesitancy in Canada, 2006/07 to 2013/14: results from cross-sectional survey data

Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013–14: Results from the InNHOVE network

Effectiveness of the influenza vaccine in preventing admission to hospital and death in people with type 2 diabetes

Contact Info

Product

Resources

About